Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Sponsor: Bio Products Laboratory (BPL)
This observational or N/A phase trial investigates Primary Immunodeficiency Disease (PIDD) and is currently completed. Bio Products Laboratory (BPL) leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2019 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
May 2019 — Sep 2019 [monthly]
Active Not Recruiting
▶ Show 5 earlier versions
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Apr 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Recruiting NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bio Products Laboratory (BPL)
- BriovaRx Infusion Services
For direct contact, visit the study record on ClinicalTrials.gov .